Inceptua Early Access and Sentynl Therapeutics launch Early Access Programme for Nulibry for paediatric patients with Molybdenum Cofactor Deficiency Type A
Inceptua Early Access and Sentynl Therapeutics, a U.S.-based biopharmaceutical company focused on bringing innovative therapies to patients living with rare diseases have entered into a partnership to make Sentynl’s Nulibry available via an Early Access Program for eligible patients with molyb- denum cofactor deficiency (MoCD) Type A.
